Research

Posted on by neuroadmin

The ENNI Lab is funded through active Research Grants via the Research Committee (RC) of the University (Aristotle University of Thessaloniki, A.U.Th.). The main types of the Grants are:

  1. Multicenter clinical trials, conducted in the B’ Department of Neurology.

  2. Sponsorships from Pharmaceutical Companies and Foundations.

  3. National, European and Intra-National research programms.

For more details related to the Lab Research activities per field, please refer to the list on the left of this page.

ONGOING RESEARCH GRANTS

The ongoing active grants support the activities of the Lab through employees wages, obtainment of scientific equipment and purchase of chemical reagents for the various projects. New equipment is mainly supported by Sponsorships.

The ongoing Grants are the following:

  1. 1. A Dose-Blind, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of Two Doses of BG00012 Monotherapy in Subjects With Relapsing-Remitting Multiple Sclerosis (109MS303). Site Principal Investigator: N. Grigoriadis. A.U.Th. RC code: 85615.
  2. 2. TOP Study: International Observational program for TYSABRI (ΙΜΑ-06-02). Site Principal Investigator: N. Grigoriadis. A.U.Th. RC code: 84811. The study continues and has been renamed to “TOPICS”.
  3. 3. A phase IV, non-intervention, international, internet-based observation study for 2 years, in patients with relapsing remitting Multiple Sclerosis that have previously changed from any disease immunomodulating treatment to Glatiramer  acetate (Copaxone) (COPTIMIZE MS-GA-401). Site Principle Investigator: N. Grigoriadis. A.U.Th. RC code: 86702.
  4. 4. Multicenter, Double-blind, Randomized, Parallel-group, Monotherapy, Active-control Study to Determine the Efficacy and Safety of Daclizumab High Yield Process (DAC HYP) Versus Avonex® (Interferon β 1a) in Patients With Relapsing-Remitting Multiple Sclerosis (DECIDE 205MS301). Site Principal Investigator: N. Grigoriadis. A.U.Th. RC code: 88007.
  5. 5. FIGHT (Phase IV clinical trial for interferon-b 1b. Site Principal Investigator: N. Grigoriadis. A.U.Th. RC code: 87717.
  6. 6. Synaptic changes after transplantation of Neural Precursor Stem cells of the Cnetral Nervous System in the experimental autoimmune encephalomyelitis: correlation study with confocal and electron microscopy and 3D-image reconstruction studies. Hellenic General Secretary for Research and Technology (GSRT): Greek-French Cooperative Grant. A.U.Th. RC code: 84673.
  7. 7. Lymphocytic adhesion molecules in Experimental autoimmune encephalomyelitis. Project leader: N. Grigoriadis. A.U.Th. RC code: 85273.
  8. 8. Molecular signals of axonal regeneration in Experimental autoimmune encephalomyelitis. Project leader: N. Grigoriadis. A.U.Th. RC code: 86996.
  9. 9. Molecular signaling of axonal injury and loss in Experimental autoimmune encephalomyelitis. Project leader: N. Grigoriadis. A.U.Th. RC code: 87283.
  10. 10. Adaptation of transplanted neural precursor stem cells in Experimental autoimmune encephalomyelitis. Project leader: N. Grigoriadis. A.U.Th. RC code: 87866.

COMPLETED RESEARCH PROGRAMS AND FUNDS

The following list includes studies and Research programs that have been completed. Their results have been published in International Scientific Meetings and/or peer-reviewed Journals.

  1. EDMUS – European Database for Multiple Sclerosis. European Concerted Action in cooperation with 10 European MS centers (Project leader: Prof. C. Confavreaux, France).
  2. PRESTISMUS – Predictive estimates in Multiple Sclerosis. European Concerted Action in cooperation with 11 European MS centers (Project leader: Prof. C. Confavreaux, France).
  3. MARCH – Multiple Sclerosis and Rehabilitation, Care and Health Services Research in Europe. European Concerted Action in cooperation with 13 European MS centers (Project leader: Prof. Dr. Ketelaer, Belgium).
  4. REMOC – Rehabilitation in Multiple Sclerosis. Outcome measurement and Cost-effectiveness in cooperation with 14 European MS centers (Project leader: Prof. Dr. Ketelaer, Belgium).
  5. Hydrolytic Enzymes in Multiple Sclerosis Treatment in cooperation with 4 MS centers from the European Union.
  6. European multicenter study to determine the efficacy and safety of Linomide in patients with Relapsing-Remitting Multiple Sclerosis. The study was withheld due to drug cardiotoxicity.
  7. GAMES – Multicenter European study on the Genetics of Multiple Sclerosis. (Project leader: Prof. A. Compston, Cambridge UK).
  8. Transplantation of Neural Precursor Stem cells (NPCs) of the Central Nervous System in Experimental Autoimmune Encephalomyelitis. Hellenic General Secretary for Research and Technology (GSRT) code: 01ΕΔ244. Project Leader: N. Grigoriadis, A.U.Th. RC code: 10084.
  9. Identification of Neutralizing antibodies (Nabs) against bioactive molecules (Interferons-beta, erythropoietin) that are used in the clinical treatment. Project Leader: N. Grigoriadis, A.U.Th. RC code: 21580.
  10. Time-sequencing of inflammation and axonopathy in the model of Experimental Autoimmune Encephalomyelitis. Project Leader: N. Grigoriadis, A.U.Th. RC code: 21581.
  11. “PYTHAGORAS-I”: Migration and differentiation of bone marrow stromal cells (BMSCs) after transplantation in an experimental model of Multiple Sclerosis. Project Leader: N. Grigoriadis, A.U.Th. RC code: 21966.
  12.  Study of the population of T-regulatory cells and BDNF expression in patients with Multiple Sclerosis.  Project Leader: N. Grigoriadis, A.U.Th. RC code: 22005.
  13. “PYTHAGORAS-II”: Migration and differentiation of bone marrow stromal cells (BMSCs) after transplantation in an experimental model of focal brain ischemia. Project Leader: N. Grigoriadis, A.U.Th. RC code: 81021
  14. National multicentre clinical study of interferon-b treatment change from low- to high- dose scheme in patients with relapsing-remitting MS (OITIMS). The Study included 10 National MS centers or Neurological Departments of Greece. Project Leader: N. Grigoriadis.
  15. Study of glial cells in an experimental model of Parkinson disease. Project Leader: N. Grigoriadis, A.U.Th. RC code: 81883.
  16. International, Randomized, Multicenter, Phase IIIb Study in Patients With Relapsing-Remitting Multiple Sclerosis Comparing Over a Treatment Period of at Least 104 Weeks (BEYOND). Site Principal Investigator: N. Grigoriadis, A.U.Th. RC code: 80105.
  17. Bodosakis Foundation sponsorships program 2011: Sponsorship for a Flow Cytometry Analysis System (FACS analysis). This equipment has been used for the FACS analysis Unit of the Lab.
  18. Bodosakis Foundation sponsorships program 2007: Sponsorship for a Laser Doppler Flowmetry (LDF) and a Blood Pressure Monitoring system (BPM) in small animals. This equipment has been used for the Experimental Stroke Unit of the Lab.
  19. Bodosakis Foundation sponsorships program 2005: Sponsorship for a Inverted Microscope, which has been used as part of a Confocal Microscopy System. This equipment has been used for the Microscopy Unit of the Lab.
  20. Bodosakis Foundation sponsorships program 2001: Sponsorship for a Carl-Zeiss optical and fluorescent microscope. This equipment has been used for the Microscopy Unit of the Lab.
  21. Empirikeion Foundation sponsorships program 2005: Sponsorship for a small animal ventilator. This equipment has been used for the Experimental Stroke Unit of the Lab.
  22. Central Macedonia Regional Operational Programme (ROP), 2007: equipment grant for a small animal anesthesia machine, with halothane vaporizateur. This equipment has been used for the Experimental Stroke Unit of the Lab.
  23. A National multicenter study to determine the action of interferon-beta 1b (BETAFERON) as an early treatment for the monosymptomatic Multiple Sclerosis (BEST). Site Principle Investigator: N. Grigoriadis.
  24. A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Dose-Comparison Study to Determine the Efficacy and Safety of BG00012 in Subjects With Relapsing-Remitting Multiple Sclerosis (DEFINE, 109MS301). Site Principle Investigator: N. Grigoriadis. A.U.Th. RC code: 83059). The study has been completed and its results have been recently published (NEJM 2012 Sep 20;367(12):1098-107).
  25. A Multi-center, Randomized, Parallel-group, Rater-blinded Study Comparing the Effectiveness and Safety of Teriflunomide and Interferon Beta-1a in Patients With Relapsing Multiple Sclerosis Plus a Long Term Extension Period (TENERE, EFC10891). Site Principal Investigator: N. Grigoriadis.
  26. A Multicenter, Randomized, Open-Label, Parallel-Group, Active-Controlled Study to Evaluate the Benefits of Switching Therapy (Glatiramer Acetate or Interferon Beta-1a) to Natalizumab in Subjects With Relapsing Remitting Multiple Sclerosis (SURPASS 101MS325). Site Principal Investigator: N. Grigoriadis. The study was prematurely terminated -globally- by BIOGEN due to insufficient patient recruitment.